Method of treating neurological diseases

A compound having a structural formula (I)

• wherein Y is selected from the group consisting of null, C1-8alkylene, NRb, C(═O), C(═O)C1-6alkylene, C1-8alkyleneNRb, C1-4alkylenearyleneC1-4alkylene, C2-6alkenylene, C4-8alkdienylene, C1-6alkylenearylene, C(═O) arylene, C(═O)C1-6alkylenearylene, C1-6alkylenepiperidinyl, and C2-6alkenylenearyleneC1-4alkylene;
• and
• Z is selected from the group consisting of
• —C3-10alkyleneSAc, —C(═O)N(Rc)OH,
• —SO2NHRc, —NHSO2NHRc, —NHSO2C1-6alkyl, —SO2C1-6alkyl,
• —C(═O)Rf wherein Rf is selected from the group consisting of OH, N(Rc)2, NH(OCH3), N(CH3)OH, C1-6alkyl, CF3, aryl, heteroaryl, C3-8cycloalkyl, heterocycloalkyl, NHSO2CH3, NHSO2CF3, and C1-6haloalkyl, —C(═O)(C(Rc)2)1-3SH, —SRd wherein Rd is hydrogen or (C═O)CH3,
• —S—(C═O)C1-6alkyl, heterocycloalkyl optionally substituted with oxo (═O), thioxo (═S), or both, heteroaryl optionally substituted with —NH2, —SH, or both, —N(H)C(═O)SH, —NHC(═O)NHRe, —NHC(═O)CH2Re, —NHC(═O)(CH2)1-6SH, —NHC(═O)CH2Hal, —NHC(═S)NHRe, —NHC(═S)CH2Re, —C(═S)NHRe, —C(═S)CH2Re, —NHC(═S)CH2Re, —NHC(═S)CH2Hal, and —(C═O)C1-3alkyl;
• Rb, independently, is selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, C3-8cycloalkyl, and heterocycloalkyl;
• Rc, independently, is selected from the group consisting of hydrogen, (C═O)CH3, C1-6alkyl, CF3, CH2F, and aryl, or two Rc groups are taken together with the carbon to which they attached to form a C3-8cycloalkyl group;
• and
• Re is NH2 or OH;
• or a pharmaceutically acceptable salt, hydrate, or prodrug thereof.